Inspire Medical Systems (INSP) saw its stock soar 7.41% in pre-market trading on Tuesday, following the release of impressive third-quarter financial results, raised full-year guidance, and a notable analyst upgrade. The medical device company, known for its innovative sleep apnea treatment, has outperformed market expectations and demonstrated strong growth prospects.

Inspire Medical reported a quarterly adjusted earnings per share (EPS) of $0.38, significantly beating the analyst consensus estimate of $(0.19). This represents a remarkable 295.88% surprise to the upside. The company's Q3 revenue reached $224.5 million, surpassing analyst estimates and marking a 10.49% increase year-over-year. In response to the strong performance, Inspire Medical raised its full-year outlook, now expecting diluted net income per share to be between $0.90 and $1.00, up from previous estimates.

The company's successful transition to the new Inspire V system appears to be a key driver behind the stock's rally. The system has received positive feedback from clinicians, with reports of 100% successful device implants and reduced surgical times. This transition has not only contributed to revenue growth but also improved gross margins due to lower cost of goods sold. Adding to the positive momentum, Wells Fargo upgraded Inspire Medical to Overweight from Equal Weight, although they adjusted their price target to $90 from $101. This upgrade, along with several other analyst actions, reflects growing confidence in the company's future prospects despite some price target reductions from other firms.